Sarepta Therapeutics, Inc.

SRPT

US8036071004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-19 pm EDT			5-day change	1st Jan Change
127.10 ^USD	+1.67%		+1.40%	+31.81%

Sep. 16	Sarepta Therapeutics, Inc. Announces Appointment of Deirdre P. Connelly to Its Board of Directors	CI
Sep. 06	Sarepta Therapeutics, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-06-2024 09:15 AM

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2025

August 07, 2024 at 04:05 pm EDT

Sarepta Therapeutics, Inc. provided revenue guidance for the year 2025. For the year, the company expects net product revenues guidance of $2.9 billion to $3.1 billion.

Latest news about Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. Announces Appointment of Deirdre P. Connelly to Its Board of Directors	Sep. 16	CI
Sarepta Therapeutics, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-06-2024 09:15 AM	Sep. 06
Sarepta Therapeutics Insider Bought Shares Worth $4,955,728, According to a Recent SEC Filing	Aug. 20	MT
Wall Street gets PPI relief, eyes now on CPI	Aug. 13
Analyst recommendations: Dell, Palo Alto Networks, Snowflake, Warner Bros, Stellantis...	Aug. 13
UBS Raises Sarepta Therapeutics Price Target to $188 From $173, Maintains Buy Rating	Aug. 09	MT
Evercore ISI Upgrades Sarepta Therapeutics to Outperform From In Line, Adjusts Price Target to $179 From $185	Aug. 08	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q2 Revenue $362.9M, vs. Street Est of $387.8M	Aug. 07	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q2 EPS $0.44, vs. Street Est of $0.47	Aug. 07	MT
Sarepta Therapeutics Swings to Q2 Non-GAAP Earnings; Revenue Rises	Aug. 07	MT
Sarepta Therapeutics, Inc., Q2 2024 Earnings Call, Aug 07, 2024	Aug. 07
Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2025	Aug. 07	CI
Sarepta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 07	CI
Sarepta Therapeutics Poised for 'Significant Launch Inflection' Amid Positive Elevidys Feedback, RBC Says	Jul. 29	MT
Central bank circus: Fed, BOJ, and BOE take the stage	Jul. 29
RBC Upgrades Sarepta Therapeutics to Outperform From Sector Perform, Keeps Price Target at $182	Jul. 29	MT
Analyst recommendations: Apple, Alphabet, Fortinet, 3M Company, IBM...	Jul. 29
Monetary policy is getting even more confusing	Jun. 26
Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172	Jun. 26	MT
Citigroup Upgrades Sarepta Therapeutics to Neutral From Buy, Adjusts PT to $176 From $172	Jun. 26	MT
Analyst recommendations: Accenture, Chipotle, Rivian, Walmart, Humana...	Jun. 26
Morgan Stanley Adjusts Sarepta Therapeutics' Price Target to $200 From $165, Keeps Overweight Rating	Jun. 24	MT
Evercore ISI Raises Price Target on Sarepta Therapeutics to $185 From $139, Maintains In Line Rating	Jun. 24	MT
Key week for monetary policy	Jun. 24
BMO Capital Raises Price Target on Sarepta Therapeutics to $200 From $170, Maintains Outperform Rating	Jun. 24	MT

Chart Sarepta Therapeutics, Inc.

Duration

Period

More charts

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Employees

1,314

Sector

Biotechnology & Medical Research

Calendar

2024-10-29 - Q3 2024 Earnings Release (Projected)

More about the company